PESTO Trial Results: What Stroke Survivors Need to Know About Perispinal Etanercept
If you’ve spent any time in stroke recovery communities, you’ve probably seen the same pattern: a treatment gets talked about with real intensity, people share personal stories that pull you in, and suddenly you’re left trying to sort hope from hype from “maybe.” When the decision also involves significant cost, that uncertainty can feel even heavier.
That’s exactly why I recorded this episode: to help stroke survivors and their families understand the PESTO trial results in plain language without drama, without attacks, and without jumping to conclusions.
In this interview, Professor Vincent Thijs explains what the PESTO trial set out to test, why it was designed the way it was, and what the results can (and can’t) tell us about perispinal etanercept in stroke recovery.
The real problem: not “hope vs skepticism”… it’s confusion
If you’re a stroke survivor, you’re already doing something heroic: you’re living inside a recovery journey that demands patience, grit, and constant adjustment.
The challenge isn’t that you “don’t want to believe” in something. The challenge is that it’s genuinely hard to make an informed decision when:
- People report different outcomes
- Online conversations become polarised fast
- Scientific studies use unfamiliar language
- The same treatment can be described in completely different ways depending on who you’re listening to
My goal here isn’t to tell you what to do. It’s to help you think clearly, ask better questions, and understand what the best available evidence from this trial actually tested.
What the PESTO trial was trying to investigate (in simple terms)
Professor Thijs explains that the PESTO trial was designed in response to strong community interest. Stroke survivors wanted to know whether the way perispinal etanercept is currently administered in some settings could be demonstrated to work under the standards used for medicines to become widely accepted as part of routine care.
So the researchers designed a randomized, placebo-controlled clinical trial. In this type of study:
- A computer assigns participants to either the treatment or a placebo
- Participants and clinicians are kept “blinded” (they don’t know who got what)
- Outcomes are measured in a consistent way at set time points
In the PESTO trial, the focus was on stroke survivors with moderate to severe disability and reduced quality of life. The primary question was straightforward:
Does quality of life improve after one or two injections compared with placebo, over the measured timeframe?
Why this study looked at quality of life (not one symptom)
One key detail Professor Thijs highlights is the design choice: the trial didn’t only target one issue, like pain or walking. It aimed to be more “pragmatic,” reflecting how treatment is used in real-world settings where people seek help for different post-stroke challenges (mobility, fatigue, speech, cognition, pain, and more).
That means the main outcome wasn’t “Did walking speed improve?” or “Did pain reduce?” It was broader:
- Quality of life at 28 days
- And again after the second injection timeframe (56 days total)
This matters because your results can look different depending on what you measure. A trial targeting one symptom might see a signal that a broad quality-of-life measure doesn’t detect (and vice versa).
What the PESTO trial results found
In Professor Thijs’ words, the trial did not show a difference in quality of life between the treatment and placebo groups at the measured time points:
- No clear quality-of-life improvement at 28 days
- No clear improvement after two injections at 56 days
That’s the central outcome.
But there’s another finding that grabbed my attention—and it’s one many listeners will find surprising.
Quote block (mid-article):
“We saw that 58% of the people also had that improvement [with placebo] and 53% had it with etanercept… our initial guess was very wrong.”
— Professor Vincent Thijs
The “placebo signal” and why it matters
A strong placebo response doesn’t mean “it was all in their heads.” It means that in a blinded clinical trial, people can improve for multiple reasons that aren’t specific to the drug itself, such as:
- Expectation and hope
- Natural fluctuations in symptoms
- The impact of being monitored and supported
- Regression to the mean (symptoms often move toward average over time)
- The structure and attention that come with trial participation
Professor Thijs describes how, during the blinded phase, participants reported improvements in a variety of areas (like sensation, vision, speech). The crucial point is: the team didn’t know who had a placebo or an active treatment at the time, which is exactly why blinding exists.
For you, the listener, this is a reminder of something empowering:
Personal stories can be real and meaningful—and still not answer the question of efficacy on their own.
“Am I a candidate?” The trial’s honest answer: we don’t know how to predict it (yet)
One of the most important parts of this conversation is the desire to identify who might benefit most.
Professor Thijs explains that the team looked at subgroups (for example: age, sex, severity, diabetes, time since stroke). In this trial, they didn’t find a clear subgroup where the treatment stood out as reliably beneficial compared with placebo.
He also adds an important caveat: subgroup analysis is difficult, especially in trials that aren’t extremely large. So the absence of a clear “responder profile” here doesn’t automatically prove none exists—it means this trial didn’t reveal one.
What this episode is (and isn’t) saying
Let’s keep this grounded and fair.
This interview is not about attacking any person, provider, or clinic. It’s not about shaming stroke survivors who tried something. It’s not even about telling you that you should or shouldn’t pursue a treatment.
It is about this:
- Understanding what the PESTO trial tested
- Understanding what the results showed within their timeframe
- Knowing the limits of what the trial can conclude
- Using evidence to reduce confusion before making big decisions
A simple “clarity plan” before you decide anything big
If you’re considering any high-stakes treatment decision, here’s a neutral, practical way to move forward:
1) Ask: “What outcome matters most for me?”
Is it pain? walking? fatigue? speech? cognition? daily function? quality of life?
A treatment might be studied for one outcome and discussed online for another.
2) Ask: “What does the best evidence say—specifically?”
Not “Does it work?” in general, but:
- In what population?
- Using what method?
- At what dose?
- Over what timeframe?
- Compared with what?
3) Ask: “What are my options and trade-offs?”
Talk with a qualified healthcare professional who understands your medical history, risk factors, and rehab plan. Ask about:
- Potential risks and side effects
- Opportunity cost (what else could you do with the same time, money, and energy?)
- Evidence-based rehab and supports that match your goals
Listen to the full interview
If you want the clearest explanation of the PESTO trial results—from the lead researcher himself—listen to the full episode with Professor Vincent Thijs.
And if you’d like to support the podcast (and help keep these conversations going for stroke survivors who need hope and clarity):
- Bill’s book: recoveryafterstroke.com/book
- Patreon: patreon.com/recoveryafterstroke
Medical disclaimer
This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan.
PESTO Trial Results (Etanercept After Stroke) | Interview with Professor Vincent Thijs
Confused about perispinal etanercept after stroke? Prof Vincent Thijs explains the PESTO trial results clearly, calmly, and evidence-first.
More About Perispinal Etanercept:
Etanercept Stroke Recovery: Wesley Ray’s Relentless Comeback
Dwayne Semple’s Remarkable Stroke Journey and Perispinal Etanercept
Etanercept for Stroke Recovery – Andrew Stopps
Support The Recovery After Stroke Podcast on Patreon
Highlights:
00:00 Introduction and Overview of the PESTO Trial
04:19 Design and Objectives of the PESTO Trial
11:23 Recruitment and Methodology of the Trial
18:31 PESTO Trial Results and Findings
24:28 Implications and Future Directions for Research
32:15 Conclusions and Final Thoughts
